FAQ: NanoViricides' NV-387 Anti-Measles Breakthrough and Clinical Progress
Summary
NanoViricides' lead drug candidate NV-387 demonstrated potent anti-Measles activity in preclinical studies, showing 130% extended survival and lung tissue protection in severe infection models. With no approved Measles treatments currently available, NV-387 represents a promising broad-spectrum antiviral candidate that has completed Phase I human trials safely and is advancing to Phase II for MPox.
What is the main announcement from NanoViricides regarding NV-387?
NanoViricides announced that their lead drug candidate NV-387 showed strong anti-Measles activity in both cell culture and humanized animal models, extending survival by 130% and protecting lung tissue in severe infection stages.
Why is this anti-Measles finding significant?
This is significant because there are currently no approved treatments for Measles, making NV-387’s potent activity a potential breakthrough for managing this serious viral infection.
What is NanoViricides’ current clinical development status for NV-387?
NV-387 has completed Phase I human trials with no reportable adverse events and is advancing to Phase II clinical trials for MPox, while the company is positioned to support FDA emergency use applications for urgent Measles cases.
What other viral infections is NV-387 being developed to treat?
NV-387 is planned as a broad-spectrum antiviral treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.
What is NanoViricides’ business model and technology platform?
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy using their nanoviricide technology, which is based on intellectual property licensed from TheraCour Pharma, Inc.
Who discussed these findings and where can I watch the interview?
CEO Dr. Anil Diwan discussed these advances during a video interview with Proactive, available at https://youtu.be/m_3Yk4_832E.
What other drug candidates does NanoViricides have in development?
The company’s other advanced drug candidate is NV-HHV-1 for the treatment of Shingles, and they are developing drugs against numerous other viral diseases including herpes, influenza, HIV, hepatitis, and Ebola.
How does NanoViricides’ technology licensing work?
The company holds exclusive, sub-licensable field licenses from TheraCour Pharma for specific viral diseases and intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses.
Where can I find more detailed information about this announcement?
The full press release is available at https://ibn.fm/uqiWa, and more company information can be found at their website https://www.nanoviricides.com/.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 268699